Citations

Clear

3942 citation(s) found for "To, Van".

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma
Sullivan, Ryan J. , Najjar, Yana G. , Akkooi, Alexander C. J. van , Menzies, Alexander M, Long, Georgina V, Taylor, Amelia M., Haanen, John, Zijlker, Lisanne P. , Davis, Keith L. , Karanth, Siddharth , Norton, Deborah , Connolly, Lucy, Long, Georgina V. , Karanth, Siddharth , Long, Georgina V , Weber, Jeffrey S. , Haque, Waqas Zia , Markovic, Svetomir N. , Salama, April K.S. , Mehmi, Inderjit , Menzies, Alexander M , Haanen, John B A G , Connolly, Lucy

Mayo Clinic

The Oncologist | November 19, 2024 | Volume: 30 | Issue: 3 | Pages: No page available

10.1093/oncolo/oyae289 | PMID 39560953 Get It

Abstract Background In BRAF-mutated high-risk melanoma, targeted therapy (BRAF/MEK inhibitors) and checkpoint inhibitor (CPI) immunotherapy have durable benefits as first-line (1L) adjuvant therapy. Based on differing action mechanisms of BRAF/MEK inhibitors and CPI immunotherapies, there is interest in evaluating the activity of 2L adjuvant targeted therapy in decreasing the risk of subsequent recurrence after repeat resection following relapse on/after 1L adjuvant CPI. Patients and methods This was a retrospective review of BRAF V600-mutated resected stage III/IV melanoma patients in the United States, Australia, and The Netherlands who received 1L adjuvant CPI immunotherapy, relapsed locoregionally/distantly, were again resected to no evidence of disease, and received dabrafenib/trametinib (dab/tram) as 2L adjuvant therapy. The primary endpoint was relapse-free survival (RFS) from initiation of 2L adjuvant dab/tram (RFS-2), analyzed via Kaplan-Meier methods. Results Thirty-eight patients were included (median age 50 years, 63% male, 87% stage III, median follow-up 19 months from 2L dab/tram initiation). Median dab/tram duration was 10.1 months (range: 1 day–22.7 months), with half discontinuing due to progression or adverse events. Median (95% CI) RFS-2 was 18.9 (14.9–28.1) months, with 91%, 81%, and 58% remaining relapse-free at 6, 12, and 18 months, respectively. Most patients remained distant metastasis-free at 6, 12, and 18 months (97%, 85%, and 71%, respectively). Two patients were deceased at the last follow-up, with 97% alive at 18 months. Conclusions Over 80% of patients remained relapse- and metastasis-free at 12 months after 2L dab/tram initiation, with only 2 deaths observed. Dab/tram appears to have activity in the 2L adjuvant setting, although more follow-up is required.
A Cost of Illness Analysis of Children with Encephalitis Presenting to a Major Hospital in Vietnam
Hương, Nguyễn Hoàng Thiên , Toan, Nguyen Duc , Khanh, Truong Huu, Thinh, Le Quoc, Nhan, Le Nguyen Thanh, Minh, Ngo Ngọc Quang, Thoa, Nguyen Thi Kim, Hùng, Nguyễn Thanh , Quy, Dư Tuấn, Thwaites, Louise , Irani, Sarosh R. , Irani, Sarosh R , Thwaites, C Louise , Tan, Le Van , Turner, Hugo C

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | November 19, 2024 | Volume: 112 | Issue: 2 | Pages: 422-430

10.4269/ajtmh.24-0409 | PMID 39561390 Get It

ABSTRACT. Encephalitis is a significant global health problem, especially in children. Knowledge of its economic burden is essential for policymakers in prioritizing the development and implementation of interventions but remains limited. An observational study was prospectively conducted at a major children’s hospital in Ho Chi Minh City, Vietnam from 2020 to 2022. Data on direct medical costs, direct nonmedical costs, and productivity costs were collected alongside demographic information, clinical features, diagnosis, severity, and outcomes of study participants. This was used to undertake a cost of illness analysis from a societal perspective. Data were collected from a total of 164 pediatric patients. The median cost of illness was estimated at US $1,859 (interquartile range [IQR]: US $1,273–$3,128). The direct costs were the main cost driver, accounting for 83.9% of the total cost of illness (US $1,560; IQR: US $975–$2,460). The productivity costs accounted for a median of US $275 (IQR: US $154–$474). The cost of illness was higher in more severe patients, patients with sequelae, patients with morbidities, and ventilated patients. Most direct medical costs were attributed to hospitalization and resulted in out-of-pocket payments from the patient’s family (30.2%; US $316). The results showed that the cost of illness of encephalitis in children is considerable and will be useful for policymakers in prioritizing resources for the development and implementation of intervention strategies to reduce the burden of pediatric encephalitis.
Seven-year outcomes after surgical aortic valve replacement with a stented bovine pericardial bioprosthesis in over 1100 patients: a prospective multicentre analysis
Sabik, Joseph F. , Rao, Vivek , Dagenais, François, Moront, Michael G., Patel, Himanshu J. , Oh, Jae K. , Fukuhara, Shinichi , Labrousse, Louis , Günzinger, Ralf, Wu, Tianhua, Investigators, PERIGON, Pettersson, Gosta, Koprivanac, Marijan, Svensson, Lars, Brown, W Morris, Gammie, James, Dawood, Murtaza, Moront, Michael G, Raikar, Goya, Tahirkheli, Naeem, Cannon, Michael, Kress, David, Ribakove, Greg, Patel, Himanshu J, Kerendi, Faraz, Fullerton, David, Baker, Craig, Beaver, Thomas, Ramlawi, Basel, Reardon, Michael J, Aldea, Gabriel, Sundt, Thoralf, Duff, Steven, Steffen, Robert J, Kshettry, Vibhu, Borger, Michael, Takeda, Koji, Adams, David H, Fischbein, Michael, Hagberg, Robert, Ruel, Marc, Rao, Vivek, Dagenais, Francois, Cartier, Raymond, Chu, Michael, Kaufeld, Tim, Shrestha, Malakh, Alfieri, Ottavio, Bensari, Nawel, Holubec, Tomas, Weber, Alberto, Ouda, Ahmed, Falk, Volkmar, Schönhoff, Florian, Carrel, Thierry, Labrousse, Louis, Klautz, Robert J M, Leeuwen, Wouter J van, Kappetein, Ari Pieter, Walther, Thomas, Moritz, Anton, Baig, Kamran, Bapat, Vinayak, Kuhn, Elmar, Wahlers, Thorsten, Kiefer, Philipp, Misfeld, Martin, Günzinger, Ralf, Lange, Rudiger, Chu, Michael , Reardon, Michael J , Patel, Himanshu J , Labrousse, Louis , Ito, Saki , Chu, Michael W A , Reardon, Michael J. , Baig, Kamran M. , Ito, Saki , Klautz, Robert J.M. , Investigators, PERIGON, Pettersson, Gosta, Koprivanac, Marijan, Svensson, Lars, Brown, W Morris, Gammie, James, Dawood, Murtaza, Moront, Michael G, Raikar, Goya, Tahirkheli, Naeem, Cannon, Michael, Kress, David, Ribakove, Greg, Patel, Himanshu J, Kerendi, Faraz, Fullerton, David, Baker, Craig, Beaver, Thomas, Ramlawi, Basel, Reardon, Michael J, Aldea, Gabriel, Sundt, Thoralf, Duff, Steven, Steffen, Robert J, Kshettry, Vibhu, Borger, Michael, Takeda, Koji, Adams, David H, Fischbein, Michael, Hagberg, Robert, Ruel, Marc, Rao, Vivek, Dagenais, Francois, Cartier, Raymond, Chu, Michael, Kaufeld, Tim, Shrestha, Malakh, Alfieri, Ottavio, Bensari, Nawel, Holubec, Tomas, Weber, Alberto, Ouda, Ahmed, Falk, Volkmar, Schönhoff, Florian, Carrel, Thierry, Labrousse, Louis, Klautz, Robert J M, Leeuwen, Wouter J van, Kappetein, Ari Pieter, Walther, Thomas, Moritz, Anton, Baig, Kamran, Bapat, Vinayak, Kuhn, Elmar, Wahlers, Thorsten, Kiefer, Philipp, Misfeld, Martín , Günzinger, Ralf, Lange, Rudiger

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | November 18, 2024 | Volume: 67 | Issue: 1 | Pages: No page available

10.1093/ejcts/ezae414 | PMID 39565905 Get It

Abstract OBJECTIVES Safety, efficacy and durability are important considerations when selecting a bioprosthesis for aortic valve replacement (AVR). This study assessed 7-year clinical outcomes and haemodynamic performance of the Avalus bioprosthesis. METHODS Patients indicated for surgical AVR were enrolled in this prospective, nonrandomized trial, conducted across 39 sites globally. The primary end-point of this analysis was freedom from surgical explant or percutaneous valve-in-valve reintervention due to structural valve deterioration (SVD) at 7 years of follow-up, determined using Kaplan–Meier (KM) analysis. We also evaluated a composite end-point of SVD and/or severe haemodynamic dysfunction requiring reintervention. Survival, valve-related safety events and haemodynamic performance were assessed. Deaths and safety events were adjudicated by an independent clinical events committee. RESULTS A total of 1132 patients underwent surgical AVR. Mean age was 70 years; 854 patients (75%) were men. The mean STS risk of mortality was 2.0 ± 1.4%, and 659 patients (58%) had a New York Heart Association classification of I/II. One or more concomitant procedures were performed in 577 patients (51%). At 7 years, the Kaplan–Meier rate of freedom from SVD/severe haemodynamic dysfunction requiring reintervention was 1.2% (0.5–2.5%) with no cases adjudicated as SVD. The survival rate was 82.6% (79.5–85.0%). The KM event rate was 5.7% (4.3–7.7%) for reintervention, 6.3% (4.9–8.3%) for endocarditis and 0.4% (0.1–1.1%) for valve thrombosis. Mean aortic gradient, dimensionless velocity index and effective orifice area were 13.8 ± 5.9 mmHg, 0.42 ± 0.09 and 1.99 ± 0.53 cm2, respectively. CONCLUSIONS This analysis demonstrated excellent durability of the Avalus valve with good clinical outcomes and stable haemodynamic performance through 7 years of follow-up.
Surgeon preferences for self-treatment in locally advanced non–small cell lung cancer: Would we practice what we preach?
Brunelli, Alessandro , Petersen, René Horsleben , Stiles, Brendon M. , Wigle, Dennis A. , Collaborators, Platz, Joseph , Muesse, Jason , Grenda, Tyler R., Makey, Ian A. , Khandhar, Sandeep J. , Schipper, Paul H., Linsky, Paul L., Liptay, Michael J, Pechet, Taine, White, Abby , Wood, Douglas E. , Brandt, Whitney S. , Martin, Linda D., Patterson, Alec, Seder, Christopher W. , Lanita, Michael, Molena, Daniela , Lee, Jay M. , Healy, David , Decker, G. Anton , Sihoe, Alan , Zairi, Sarra , Dunning, Joel , Raveglia, Federico , Kleontas, Athanasios, Szántó, Zalán , Nosotti, Mario , Hudson, Jessica , Schneiter, Didier, Asadi, Nizar , Aranda, J.M. Botía, Congregado, Miguel , Backhus, Leah, Bertani, Alessandro , Nadal, Sergio Bolufer, Rosso, Lorenzo, Gattás, Gustavo, Augustin, Florian , Milton, Richard , Vannucci, Fernando , Waller, David , Gasparri, Mario, Reddy, Rishindra M. , Schreurs, W. H. , Saftić, Igor, Scarci, Marco, Toker, Seyfi Alper, Welcker, K , Furák, József, Durand, Marion, Hugen, Niek , Joseph, Lula Lukadi, Chiappetta, Marco , Pérez, María Rodríguez, Minasyan, Anna , Filose, Pier Luigi, Elkhayat, Hussein , Wei, Benjamin , Leone, Richard J., Chang, Albert S., Curcio, Carlo, Sparks, Preston, Hagen, Jeffrey A., Baste, Jean Marc , Taylor, Lauren , Xavier, D'journo, Hall, David Jeffrey, Hansen, Henrik Jessen, Leschber, Gunda, Koryllos, Aris , Gandhi, Shilpa , Batgirl, Hasan, Calvin, Ng Sze Hang, Sotiropoulos, Georgios C. , Furrer, Markus , Danjouma, Cheufou, Novoa, Nuria , Cassivi, Stephen D. , Veronesi, Giulia , Hamouri, Shadi , Štupnik, Tomaž , Hall, David J. , Antonoff, Mara B. , Collaborators, Louie, Brian E. , Daddi, Niccolò , Swisher, Stephen G. , Yendamuri, Sai S , Liptay, Michael J, Herrera, Luis, Martin, Linda, Patterson, Alec, Sandri, Alberto , Ruffini, Enrico , Maurizi, Giulio , Kleontas, Athanasios, Depypere, Lieven , Caruana, Edward Joseph , Mitchell, John , Gonfiotti, Alessandro , Pagès, P , Aranda, Jose, Billè, Andrea , Falcoz, Pierre‐Emmanuel , Rosso, Lorenzo , Terra, Ricardo Mingarini , Raemdonck, Dirk Van , Minervini, Fabrizio , Tosi, Davide , Solli, Piergiorgio , Scarci, Marco , Gooseman, Michael , Gossot, Dominique , Álvarez, Antonio , Toker, Seyfi Alper, Aramini, Beatrice , Guerrera, Francesco , Jiménez, Marcelo Fernando , Bölükbas, Servet , Thomas, P. A. , Luzzi, Luca , Aigner, Clemens , Minasyan, Anna, Kim, Young Tae , Pompili, Cecilia , Shargall, Yaron , Fiorelli, Alfonso , Curcio, Carlo, Bilfinger, Thomas V. , Engelhardt, Kathryn Elizabeth , Hall, David Jeffrey, Akopov, Andrey L. , Loos, Erik Robert de , Karamustafaoğlu, Yekta Altemur , Bertolaccini, Luca , Hendriks, Jeroen M. , Scanagatta, Paolo , Prisciandaro, Elena , Gómez-Hernández, María Teresa , Agrafiotis, Apostolos C. , Casiraghi, Monica , Danjouma, Cheufou Housmanou, Mariani, Alessandro Wasum , Antonio, David Gómez de , Bolca, Ciprian Nicolae , Cattaneo, Margherita

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | November 15, 2024 | Volume: 66 | Issue: 5 | Pages: No page available

10.1093/ejcts/ezae344 | PMID 39545513 Get It

Abstract 4138252: Association between Pressure-Adjusted Heart Rate and Mortality in Cardiogenic Shock
Ginder, Curtis , Guo, Jianping , Katz, Jason N. , Jentzer, Jacob C. , Guo, Jianping, Diepen, Sean van , Morrow, David A. , Berg, David D.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4138252 Get It

Introduction: Among patients with cardiogenic shock (CS), high right atrial pressure (RAP) and low mean arterial pressure (MAP) are associated with in-hospital mortality. Pressure-adjusted heart rate (PAHR), defined as heart rate * RAP-to-MAP ratio (HR * [RAP/MAP]), integrates these parameters and has been used to identify cardiovascular dysfunction in critical illness. Higher PAHR values associate with higher surgical ICU mortality, but the prognostic significance of PAHR has not been assessed in cardiac intensive care unit (CICU) patients with CS. Hypothesis: We hypothesized that higher PAHR values are associated with higher risk of in-hospital mortality in patients with CS. Methods: The Critical Care Cardiology Trials Network (CCCTN) is a multinational registry of CICUs coordinated by the TIMI Study Group. Among CS admissions (2018-2023) undergoing invasive hemodynamic assessment within 24h of CICU admission, we calculated PAHR (in bpm) and assessed its relationship with in-hospital mortality. Patients on temporary mechanical circulatory support were excluded. Odds ratios were adjusted for age, sex, vasoactive-inotropic score (VIS), SCAI stage, and preceding cardiac arrest. Subgroup analyses stratifying by CS subtype were performed. Results: Among the 1411 CS admissions in the analysis cohort (mean age 61 years, 31% women), 18% had AMI-CS, 75% had HF-CS, and 7% had secondary CS. At the time of assessment (median 1.4h after CICU admission), 75% were on vasoactive support (median VIS 3.8). Median HR was 92 (Q1-Q3 77-109) bpm, RAP 15 (Q1-Q3 10-19) mmHg, MAP 75 (Q1-Q3 67-87) mmHg, and PAHR 17 (Q1-Q3 11-24) bpm. A stepwise gradient of higher in-hospital mortality with increasing PAHR values (p-trend <0.001; Fig ) was observed. In adjusted models, a higher PAHR was associated with higher in-hospital mortality (aOR per 10-bpm, 1.35 [95% CI, 1.15-1.58]), and had stronger prognostic associations with mortality than its individual hemodynamic components (Fig) . Conclusion: Higher PAHR is strongly associated with in-hospital mortality in CS patients. PAHR, a simple parameter which is readily calculable without needing a pulmonary artery catheter, may aid in identifying CS patients at higher risk of death.
Short-term Surgical Outcomes of Papillary Craniopharyngiomas: A Multicenter Study
Catalino, Michael P. , Pham, D. T. , Pacione, Donato , Suryadevara, Carter M. , Silverstein, Julie , Gardner, Paul A. , Fernandez‐Miranda, Juan C. , Benjamin, Carolina , Kshettry, Varun R. , Zada, Gabriel , Zwagerman, Nathan T. , Cheok, Stephanie , Wu, Kyle C., Little, Andrew S. , Pham, Duy, Rennert, Robert C , Couldwell, William T. , Kim, Won Bae , Kim, Albert , Chicoine, Michael , Barkhoudarian, Garni , Gompel, Jamie J. Van , Palit, Sandhya R. , Prevedello, Daniel M. , Mamelak, Adam N. , Pacult, Mark A. , Karsy, Michael

Mayo Clinic

No container title available | November 13, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5245655/v1 Get It

Abstract Purpose: Craniopharyngiomas are rare parasellar tumors, and papillary craniopharyngiomas (PCP) represent 8-20% of cases. We assessed surgical outcomes of these very rare tumors among patients treated in the last decade. Methods: Retrospective data from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID) were used to evaluate patients with PCP treated between 2011 and 2023 at 14 US-based academic skull base centers. Demographic, imaging, surgical, and outcome variables were analyzed. Results: Ninety-nine patients with PCP were included. Mean age was 51.8±14.7 and 57.6% were male. Most tumors showed mixed cystic/solid components (67.5%), were trans-infundibular (50.0%), and were treated endoscopically (74.5%), with 51.1% demonstrating gross total resection (GTR). Pituitary stalk was preserved in 51.9%. Permanent arginine vasopressin deficiency was seen in 68.8% and was associated with pituitary stalk sacrifice (p=0.02). Cerebrospinal fluid leak was the most common nonendocrine postsurgical, 30-day complication (9.1%), reason for return to the operating room (3.1%), and reason for 90-day readmission (8.1%). Return to the operating room was associated with discharge to a skilled nursing or rehabilitation facility (p=0.0001). Most patients (63.9%) received no adjuvant therapy; GTR was associated with decreased radiotherapy use (p=0.0001). BRAFV600E mutation was detected in 64/69 tumors tested, although only 1 patient was treated with a BRAF inhibitor. Conclusion: To our knowledge, the RAPID consortium enabled the largest real-world clinical information dataset for PCP. Our data can be used as a benchmark for short-term surgical outcomes. Longer-term follow-up studies are needed to understand how to optimize outcomes from each treatment modality.
Pathologic dural invasion is associated with regional recurrence in olfactory neuroblastoma: A multi‐institutional study
Tang, Anthony , Fung, Nicholas , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Nayak, Jayakar V. , Patel, Chirag , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Nayak, Jayakar V , Patel, Zara , Pinheiro-Neto, Carlos, Snyderman, Carl H , Wang, Eric W , Choby, Garret , Hwang, Peter H , Taori, Suchet , Fung, Nicholas, Almeida, João Paulo , Pinheiro‐Neto, Carlos , Gompel, Jamie J. Van , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | November 13, 2024 | Volume: 15 | Issue: 4 | Pages: 373-383

10.1002/alr.23489 | PMID 39535364 Get It

AbstractObjectiveNeck metastases are a poor prognostic factor in olfactory neuroblastoma (ONB). Pathologic dural invasion (pathDI) may increase the risk of neck metastases due to invasion of dural lymphatics. We aim to evaluate the prognostic value of pathDI in predicting rates of neck metastases and recurrence using a large, multicenter database of ONB patients.Data sourcesRetrospective review of a prospective, multicenter database of electronic health records of all patients who presented with ONB between 2005 and 2021 at nine tertiary academic care centers within North America.Review methodsClinicopathologic features including modified Kadish staging systems, margin status, treatment modalities, Hyams grading, follow‐up time, and survival.ResultsOf 258 ONB patients, 189 patients met the inclusion criteria. The 10‐year neck recurrence‐free survival (neck‐RFS) rates were 85.7% (75.6‒97.3) and 61.8% (47.9‒79.8) for patients without and with pathDI, respectively (p = 0.018). Time‐to‐event multivariable regression analysis found pathDI to have an odds ratios of 9.7 (95% confidence interval [CI] 1.2–80.4, p = 0.04) for neck‐RFS and 9.5 for RFS at any site (95% CI 1.1–83.3, p = 0.04).ConclusionIn multivariable analysis, the presence of pathDI appears to be the strongest predictor of neck recurrence and recurrence at any site. Future studies exploring the benefit of elective neck dissection or radiation for patients with pathDI may impact disease management.
BIOM-52. THE DYNAMIC GLIOMA CSF PROTEOME: IMPACT OF LOCATION AND RESECTION FOR DISEASE MONITORING
Riviere-Cazaux, Cécile , Warrington, Arthur E. , Hoplin, Matthew D. , Andersen, Katherine, Malik, Noor , Jusué-Torres, Ignacio , Meyer, Fredric B. , Kizilbash, Sani H. , Campian, Jian , Parney, Ian, Kizilbash, Sani H , Jusue-Torres, Ignacio , Malik, Noor , Michor, Franziska , Carlstrom, Lucas P. , Ghadimi, Keyvan , Himes, Benjamin , Sarkaria, Jann N. , Gompel, Jamie J. Van , Sener, Uğur , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii31-viii32

10.1093/neuonc/noae165.0124 Get It

Abstract While serial sampling of glioma tissue is rarely performed before recurrence, cerebrospinal fluid (CSF) can be acquired serially to evaluate candidate monitoring and pharmacodynamic biomarkers in patients with gliomas. However, the impact of key variables to consider in longitudinal CSF, including anatomical location and post-surgical changes, remains unknown. To that end, pre- versus post-resection intracranial CSF samples from patients with gliomas were obtained at early (1-16 days; n=20) or delayed (86-153 days; n=11) timepoints, as well as lumbar-versus-intracranial glioma CSF samples (n=14). Using aptamer-based proteomics, we identified significant differences in the glioma CSF proteome between lumbar, subarachnoid, and ventricular CSF. Indeed, intracranial CSF in paired lumbar/intracranial samples had nearly 1600 unique aptamers, regardless of which intracranial location was compared to the paired lumbar CSF, including in enrichment style analyses that evaluated the overlap between protein states. Importantly, resection had a significant, evolving longitudinal impact on the CSF proteome, with subsets of proteins associated with early versus delayed post-resection changes, many of which were enriched for inflammatory-related pathways. Interestingly, despite increased contamination from surgical debris, enrichment for plasma-associated proteins decreased with resection (FDR: 0.000), suggesting that a portion of the baseline glioma panel could be derived from plasma-originating analytes due to blood-brain barrier disruption. Despite these challenges, our data still revealed preliminary candidate monitoring biomarkers, such as brevican, that increased with progression (example patient: fold-change of 3.58x and 2.08x through lomustine and bevacizumab, respectively), but not pseudoprogression (Fold change less than 1.5). Serial intracranial CSF samples suggested the early potential for disease monitoring and evaluation of pharmacodynamic impact of targeted therapies, including bevacizumab and pembrolizumab. In conclusion, our available data to date suggest that the intracranial glioma CSF proteome provides an abundant and evolving source of candidate biomarkers to longitudinally discern the impact of resection and systemic treatments.
INNV-27. TEMOZOLOMIDE FOR PATIENTS WITH AGGRESSIVE PITUITARY TUMORS: A CASE SERIES
Baykal, Duru, Ser, Hazal, Uhm, Joon H. , Ruff, Michael W. , Neth, Bryan J. , Giannini, Caterina, Erickson, Dana , Neth, Byran J. , White, Jessica B. , Baykal, Duru, Lachance, Daniel Honore , Gompel, Jamie J. Van , Raghunathan, Aditya , Sener, Uğur

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii174-viii174

10.1093/neuonc/noae165.0689 Get It

Abstract BACKGROUND Pituitary adenomas are often effectively managed with medical therapy, surgery, and radiation therapy. However, up to 15% of pituitary neoplasms exhibit rapid growth, invasive behavior, or, rarely, metastasize despite optimal standard treatments. Temozolomide is associated with a survival benefit for patients with these aggressive pituitary tumors. METHODS We present a case series of 8 patients with an aggressive pituitary tumor (APT) or pituitary carcinoma (PC) treated with temozolomide. RESULTS Eight patients (3 female, median age at diagnosis 44) with APT (n=6) or PC (n=2) were treated. A variety of pituitary tumor types were represented (1 prolactinoma, 5 corticotroph adenomas, 1 gonadotroph adenoma, 1 thyrotropinoma). Prior to temozolomide initiation, patients underwent a median 5 treatments including medical management (n=4), surgery (n=7), radiation therapy (n=7). Temozolomide was started at median 3.5 recurrence. Median treatment duration was 6 cycles (n=6, 150-200 mg/m2 days 1-5, 28-day cycles; n=1, 75 mg/m2, days 1-21, 28-day cycles). Seven patients experienced progression after temozolomide treatment, median progression-free survival (PFS) was 4 months. One patient remains on treatment, progression-free at 5 months. MGMT methylation status was assessed for 3 tumors. Among 2 patients with MGMT promoter methylated tumors, PFS was 4 months for one patient, the other remains on treatment. For one patient with MGMT promoter unmethylated corticotroph adenoma, PFS was 9 months. No ≥ grade 4 toxicities were noted. Most common toxicities were nausea (n=5), thrombocytopenia (n=3), and fatigue (n=2). CONCLUSION In this group of heavily pretreated patients, temozolomide monotherapy was well-tolerated and associated with median PFS of 4 months. Interestingly, PC patients had longer PFS at 9 months and 24 months. Our findings support use of single-agent temozolomide chemotherapy for patients with APT/PC, but further prospective analysis is needed to identify patients more likely to benefit from treatment and optimal timing of chemotherapy initiation.
A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases
DePalo, Danielle K. , Dugan, Michelle M. , Naqvi, Syeda Mahrukh Hussnain , Ollila, David W. , Hieken, Tina J. , Block, Matthew S. , Houdt, Winan J. van , Reijers, Sophie J. M. , Asher, Nethanel , Duncan, Zoey , Anderson, Matilda, Snow, Hayden , Held, Jenny M., Farma, Jeffrey M. , Vetto, John T. , Hui, Jane Yuet Ching , Kolbow, Madison , Saw, Robyn P.M. , Lo, Serigne , Long, Georgina V. , Karapetyan, Lilit , Akkooi, Alexander C. J. van , van Houdt, Winan J , Asher, Nethanel , Hui, Jane Yuet Ching , Kolbow, Madison , Lo, Serigne N , Thompson, John F , Zager, Jonathan S , Hieken, Tina J , Long, Georgina V , Wouters, Michel W.J.M. , Broman, Kristy K. , Gyorki, David E. , Held, Jenny, Thompson, John F. , Kim, Youngchul , Ny, Lars , Bagge, Roger Olofsson , Zager, Jonathan S.

Mayo Clinic

Cancer | November 10, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35636 | PMID 39522025 Get It

AbstractBackgroundIsolated limb infusion and perfusion (ILI/ILP) has been a mainstay treatment for unresectable melanoma in‐transit metastases (ITM), but increased use of immune checkpoint inhibitors (ICI) and intralesional therapy (talimogene laherparepvec [TVEC]) introduced several different management options. This study compares first‐line ILI/ILP, ICI, and TVEC.MethodsRetrospective review from 12 international institutions included patients treated from 1990 to 2022 with first‐line ILI/ILP, ICI, or TVEC for unresectable melanoma ITM.ResultsA total of 551 patients were treated, with ILI/ILP (n = 356), ICI (n = 125), and TVEC (n = 70) with median follow‐up of 5.5 years. Tumor burden was highest with ILI/ILP and lowest with TVEC (p = .002). Breslow thickness was lowest with TVEC (p = .007). TVEC was mostly used in stage IIIB disease versus IIIC for ILI/ILP and ICI (p = .01). Using ICI as the reference category, TVEC had the highest odds of a complete response (CR) (odds ratio, 1.96; p = .029) and a longer local progression‐free survival (PFS) (hazard ratio [HR], 0.40; p = .003). ILI/ILP had shorter local PFS (HR, 1.72; p = .012), PFS (HR, 1.79; p < .001), distant metastasis‐free survival (DMFS) (HR, 1.75; p = .014), overall survival (HR, 1.82; p = .009), and melanoma‐specific survival (HR, 2.29; p = .004). Stage IIIB disease had longer DMFS (HR, 0.24; p < .001) compared to IIIC/D.ConclusionsTVEC as first‐line therapy for unresectable melanoma ITM was associated with superior CR rates and local PFS. Notably, TVEC was used in patients with a lower Breslow thickness, disease stage, and tumor burden. Therefore, when compared to ILI/ILP and ICI, TVEC should be considered as first‐line therapy for unresectable stage IIIB melanoma ITM with minimal tumor burden and lower Breslow thickness.